Lessons Learned From Health Technology Assessment Pilot Projects to Assess Real-World Evidence’s Usefulness in Reassessments of Effectiveness and Value
Author(s)
Discussion Leader: Ashley Jaksa, MPH, Aetion, Inc, Boston, MA, USA
Discussants: Jon Campbell, PhD, Institute for Clinical and Economic Review, Hingham, MA, USA; Seamus Kent, PhD, Data and Analytics, National Institute for Health and Care Excellence (NICE), London, LON, UK; Gregory Daniel, PHD, MPH, Eli Lilly, Washington DC, DC, USA
Presentation Documents
PURPOSE: To identify and understand key learnings and challenges from two pilot projects conducted by Health Technology Assessment (HTA) agencies using real-world evidence to update prior health technology assessments. To determine best practices for RWE use in HTA assessments based on demonstration projects and audience feedback
DESCRIPTION: HTA agencies traditionally use real-world evidence (RWE) as economic modeling inputs for one-time HTA assessment after regulatory approval. More recently, HTA agencies are considerings shifting toward assessing drugs at multiple timepoints throughout the product’s lifecycle. To better understand the role of RWE in serial HTA assessments, ICER and NICE conducted pilot projects to update prior HTA assessments. Key learnings from these pilot projects will inform future RWE guidances and best practices.
An overview of the current RWE guidances for HTA assessments and an introduction to the pilot projects will be provided (Ashley Jaksa). ICER and NICE representatives will provide in-depth examination of the pilot projects and key learnings from each study. Speakers will also explore tenets of RWE best practices and guidances based on the pilot studies (Jon Campbell and Seamus Kent). The industry representative will share experiences with conducting RWE within their institution and discuss collaborative approaches to providing this evidence to payers for future assessments (Gregory Daniel). The speakers will share insights and lessons learned from each demonstration project that will eventually inform institutional best practices and future guidances on RWE use in HTAs. The speakers will solicit public comments and immediate feedback by conducting real-time polling to key learnings. The audience is expected to participate and provide their perspective and experience regarding RWE best practices.Conference/Value in Health Info
Code
206
Topic
Health Technology Assessment